ForPatients

by Roche

Respiratory Disorder

A Study of Pirfenidone in Patients With Unclassifiable Progressive Fibrosing Interstitial Lung Disease

Trial Status Trial Runs In Trial Identifier
Completed 14 Countries NCT03099187 2016-002744-17
MA39189

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

The purpose of this study is to evaluate the efficacy and safety of pirfenidone in participants with fibrosing interstitial lung disease (ILD) who cannot be classified with moderate or high confidence into any other category of fibrosing ILD by multidisciplinary team (MDT) review ("unclassifiable" ILD).

Hoffmann-La Roche Sponsor	Phase 2 Phase	
NCT03099187 2016-002744-17 MA39189 Trial Identifiers		
Eligibility Criteria	<i>ı</i> :	
Gender All	Age >=18 Years & <= 85 Years	Healthy Volunteers